Bristol-Myers Squibb chooses UCLA as latest research partner
pharmafile | December 14, 2015 | News story | Manufacturing and Production, Research and Development | BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla
Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as part of a research program in the US.
The company’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program is an initiative BMS is running with academic-based cancer research centres, focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
The US firm has already agreed a deal with Johns Hopkins University, to conduct a range of early stage clinical studies, as part of the program. BMS is also working with the Moffatt Cancer Centre in Florida as part of the program.
Bristol-Myers Squibb and the David Geffen School of Medicine at UCLA will conduct a range of early phase clinical studies as part of the I-O RPM research program, and Bristol-Myers Squibb will fund positions within UCLA’s fellowship program in the UCLA Division of haematology and oncology.]
“The I-O RPM research program is an important complement to Bristol-Myers Squibb’s broad research and development program for immuno-oncology,” says Dr Laura Bessen, who is head of US medical at Bristol-Myers Squibb. She adds: “We look forward to working with UCLA in an effort to continue advancing the science in this innovative field of research and cancer treatment.”
The I-O RPM research program focuses on significant areas of high unmet need marked by poor outcomes among patients with rare population malignancies: a subpopulation within a higher incident disease population. These patients have aggressive disease with an increased potential for early metastasis to multiple sites and/or are initially refractory or subject to early recurrences with conventional cancer therapies.
Lilian Anekwe
Related Content
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
Meteor Biotech opens site at UCLA to support biotech research
South Korean spatial omics specialist, Meteor Biotech, has announced the opening of its first international …
Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …
